SCHEMBL20565255

SCHEMBL20565255

COc1ccc(CC(=O)O)c(Cl)n1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
HSD17B10 Q99714 1/20 0.41
NNMT P40261 2/20 0.39
RECQL P46063 1/20 0.39
PTGS1 P23219 1/20 0.38
AKR1C3 P42330 1/20 0.38
AKR1C2 P52895 1/20 0.38
CXCL8 P10145 1/20 0.37
MMP2 P08253 1/20 0.37
MMP9 P14780 1/20 0.37
MMP12 P39900 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.36
KDM4E B2RXH2 2/20 0.36
MTNR1A P48039 3/20 0.36
MTNR1B P49286 3/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30034021 1.00 POLB (0.44) POLBTDP1HSD17B10NNMTRECQL
SCHEMBL30035020 0.80 MTNR1A (0.45) POLBTDP1NNMTRECQLNPC1
SCHEMBL22045849 0.80 MTNR1A (0.45) POLBTDP1NNMTRECQLNPC1
SCHEMBL15548752 0.80 POLB (0.44) POLBTDP1HSD17B10NNMTRECQL
SCHEMBL30030651 0.79 ALDH1A1 (0.49) POLBTDP1HSD17B10NNMTRECQL
SCHEMBL20565330 0.79 ALDH1A1 (0.49) POLBTDP1HSD17B10NNMTRECQL
SCHEMBL20565701 0.77 ALDH1A1 (0.42) TDP1PTGDR2KDM4EALDH1A1
SCHEMBL30034504 0.77 ALDH1A1 (0.42) TDP1PTGDR2KDM4EALDH1A1
SCHEMBL25179865 0.77 ALDH1A1 (0.47) POLBTDP1NNMTRECQLNPC1
SCHEMBL940930 0.77 AKR1B1 (0.41) TDP1PTGS1CXCL8KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250387379-A1 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS NFLECTION THERAPEUTICS INC (US) 2025-12-25 US disclosed
EP-4233834-A2 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS NFlection Therapeutics, Inc. (US) 2023-08-30 EP disclosed
EP-4233834-A2 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS NFlection Therapeutics, Inc. (US) 2023-08-30 EP disclosed
EP-4233865-A2 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS NFlection Therapeutics, Inc. (US) 2023-08-30 EP disclosed
EP-4233865-A2 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS NFlection Therapeutics, Inc. (US) 2023-08-30 EP disclosed
US-20230013227-A1 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS NFLECTION THERAPEUTICS, INC. 2023-01-19 US disclosed
US-20230013227-A1 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS NFLECTION THERAPEUTICS, INC. 2023-01-19 US disclosed
US-11542271-B2 Fused heteroaromatic-aniline compounds for treatment of dermal disorders NFLECTION THERAPEUTICS, INC. (US) 2023-01-03 US disclosed
US-11542271-B2 Fused heteroaromatic-aniline compounds for treatment of dermal disorders NFLECTION THERAPEUTICS, INC. (US) 2023-01-03 US disclosed
CN-111093658-B Fused heteroaromatic-aniline compounds for the treatment of skin diseases 恩福莱克逊治疗有限公司 2022-10-14 CN disclosed
CN-113645964-A Arylaniline and heteroarylaniline compounds for use in fetal marker therapy 恩福莱克逊治疗有限公司 2021-11-12 CN disclosed
EP-3883554-A1 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS NFlection Therapeutics, Inc. (US) 2021-09-29 EP disclosed
EP-3883553-A1 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS NFlection Therapeutics, Inc. (US) 2021-09-29 EP disclosed
US-10988483-B2 Fused heteroaromatic-aniline compounds for treatment of dermal disorders NFLECTION THERAPEUTICS, INC. (MA) 2021-04-27 US disclosed
US-10988483-B2 Fused heteroaromatic-aniline compounds for treatment of dermal disorders NFLECTION THERAPEUTICS, INC. (MA) 2021-04-27 US disclosed
US-20200172550-A1 FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS NFLECTION THERAPEUTICS, INC. 2020-06-04 US disclosed
US-20200172550-A1 FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS NFLECTION THERAPEUTICS, INC. 2020-06-04 US disclosed
CN-111093658-A Fused heteroaromatic-aniline compounds for the treatment of skin diseases 恩福莱克逊治疗有限公司 2020-05-01 CN disclosed
EP-3624795-A1 FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS NFlection Therapeutics, Inc. (US) 2020-03-25 EP disclosed
WO-2018213807-A1 FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS NFLECTION THERAPEUTICS, INC. (US) 2018-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230013227-A1 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS HTR3C, NDUFA13, NDUFAF3 POLB 1503/4885TDP1 2533/4885HSD17B10 756/4885
US-10988483-B2 Fused heteroaromatic-aniline compounds for treatment of dermal disorders TYR, CYP19A1, BRAF POLB 142/4885TDP1 367/4885HSD17B10 271/4885
US-20200172550-A1 FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS TYR, CYP19A1, BRAF POLB 142/4885TDP1 367/4885HSD17B10 271/4885
US-11542271-B2 Fused heteroaromatic-aniline compounds for treatment of dermal disorders TYR, CYP19A1, BRAF POLB 138/4885TDP1 368/4885HSD17B10 278/4885
US-20250387379-A1 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS SUB1, AHR, NCOA3 POLB 1273/4885TDP1 1293/4885HSD17B10 1260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.